Amgen completed construction of its first next-generation biomanufacturing facility in Singapore. The plant employs single-use bioreactors, disposable plastic containers, continuous purification processing, and real-time quality analysis, according to an Amgen official, who added that this “flexible, modular design can be replicated in future facilities, enabling higher production and greater accessibility to patients around the world.”
“At Amgen, we are reinventing what it means to manufacture biologic medicines,” said Robert A. Bradway, chairman and CEO of Amgen. “Singapore is an ideal place to invest in such a pioneering facility because of its talented workforce and commitment to the biotechnology industry.”
The facility is expected to have the same annual output as a conventional facility but in a single building that will use less energy and water and have lower solid waste and emission levels, explained Bradway.